HC Wainwright Reaffirms “Buy” Rating for Arcturus Therapeutics (NASDAQ:ARCT)

Arcturus Therapeutics (NASDAQ:ARCT)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $63.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 280.21% from the stock’s current price.

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, December 16th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $66.75.

Arcturus Therapeutics Trading Down 7.8 %

NASDAQ ARCT traded down $1.41 during trading hours on Monday, hitting $16.57. 116,218 shares of the company’s stock traded hands, compared to its average volume of 432,685. The firm has a market capitalization of $448.83 million, a P/E ratio of -7.46 and a beta of 2.63. The business’s fifty day moving average price is $17.62 and its two-hundred day moving average price is $20.05. Arcturus Therapeutics has a 52 week low of $14.30 and a 52 week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.44. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The company had revenue of $41.67 million during the quarter, compared to analysts’ expectations of $49.16 million. During the same period last year, the company posted ($0.61) earnings per share. On average, sell-side analysts expect that Arcturus Therapeutics will post -2.31 EPS for the current fiscal year.

Insider Buying and Selling at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total transaction of $249,120.00. Following the sale, the chief operating officer now owns 435,334 shares of the company’s stock, valued at approximately $9,037,533.84. This trade represents a 2.68 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 15.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ARCT. nVerses Capital LLC purchased a new position in shares of Arcturus Therapeutics during the 3rd quarter valued at approximately $42,000. Quest Partners LLC grew its position in shares of Arcturus Therapeutics by 3,283.5% during the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 3,579 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Arcturus Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 2,038 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in Arcturus Therapeutics during the second quarter worth approximately $142,000. Finally, Point72 DIFC Ltd acquired a new stake in Arcturus Therapeutics in the second quarter valued at approximately $188,000. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.